Zacks: Brokerages Expect Intrexon Corporation (XON) Will Post Quarterly Sales of $48.79 Million

Wall Street analysts predict that Intrexon Corporation (NYSE:XON) will post sales of $48.79 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Intrexon’s earnings, with the lowest sales estimate coming in at $44.65 million and the highest estimate coming in at $51.91 million. Intrexon reported sales of $46.00 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.1%. The firm is scheduled to report its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Intrexon will report full-year sales of $48.79 million for the current financial year, with estimates ranging from $197.50 million to $206.11 million. For the next year, analysts expect that the firm will post sales of $249.15 million per share, with estimates ranging from $217.00 million to $281.22 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Intrexon.

A number of brokerages have recently weighed in on XON. Northland Securities set a $30.00 price objective on shares of Intrexon and gave the stock a “buy” rating in a research note on Monday, August 7th. BidaskClub cut shares of Intrexon from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. JMP Securities reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Intrexon in a research note on Thursday, October 5th. Griffin Securities reaffirmed a “buy” rating and issued a $55.00 target price on shares of Intrexon in a research note on Friday, October 6th. Finally, Bank of America lowered their target price on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Intrexon has a consensus rating of “Hold” and an average target price of $38.50.

Shares of Intrexon (NYSE XON) traded down $0.48 on Friday, hitting $12.94. 904,708 shares of the stock were exchanged, compared to its average volume of 1,141,156. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. Intrexon has a fifty-two week low of $10.26 and a fifty-two week high of $30.96.

Hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC purchased a new stake in Intrexon in the 3rd quarter worth approximately $121,000. Tower Research Capital LLC TRC grew its stake in Intrexon by 2,031.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 4,937 shares during the period. SG Americas Securities LLC purchased a new stake in Intrexon in the 3rd quarter worth approximately $139,000. Federated Investors Inc. PA purchased a new stake in Intrexon in the 2nd quarter worth approximately $172,000. Finally, Quantbot Technologies LP grew its stake in Intrexon by 423.7% in the 3rd quarter. Quantbot Technologies LP now owns 9,993 shares of the biotechnology company’s stock worth $189,000 after acquiring an additional 8,085 shares during the period. 77.49% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/05/zacks-brokerages-expect-intrexon-corporation-xon-will-post-quarterly-sales-of-48-79-million.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Get a free copy of the Zacks research report on Intrexon (XON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply